Sphingosine-l-phosphate (Sph-l-PI is the initial product of catabolism of sphingosine by sphingosine kinase and is cleaved by Sph-l-P lyase to a fatty aldehyde and ethanolamine phosphate. This phosphorylated sphingoid base is not only an intermediary catabolite, but also a bioactive lipid with important functions, including stimulation of cell proliieration in Swiss 3T3 fibroblasts and inhibition of tumor cell motility. In the present study, we examined functional roles of Sph-l-P in human platelets. Sph-l-P induced platelet shape change and aggregation reactions, although it failed to elicit secretion. Sphingosine, ceramide, sphingomyelin, and N,Ndimethylsphingosine did not mimic the positive effects of Sph-l-P on platelets. Subthreshold concentrations of Sph-l-P and weak platelet agonists such as adenosine diphosphate (ADP) and epinephrine synergistically elicited aggregation, which may be important for efficient ampliication of platelet activation. Sph-l-P induced intracellular CB2+ mobilization and the dose-response for CazC release PHINGOSINE (Sph), the fundamental backbone structure of all sphingolipids and glycosphingolipids, and its direct metabolites such as sphingosine-l-phosphate (Sph-1 -P), ceramide (Cer), and N,N-dimethylsphingosine (DMS) have been implicated as lipid second messengers or modulators of membrane signal transduction ~ystems."~ Sph-l-P is the initial product of catabolism of Sph by Sph kinase" and is then cleaved by Sph-l-P lyase to a fatty aldehyde and ethanolamine phosphateg"' or dephosphorylated by a sphingosine phosphatase, as reported recently." The phosphorylated sphingoid base Sph-l-P is not only an intermediary catabolite, but also an important bioactive compound. Sphl-P stimulates DNA synthesis and cell division in Swiss 3T3 fibroblasts, possibly via induction of Ca" mobilization or enhanced phosphatidic acid ~ynthesis.'"'~ Sph-l-P has also been implicated as a novel second messenger in plateletderived growth factor (PDGF) and serum-dependent fibroblast cell growth." In Balb/c 3T3 cells, Sph kinase was reported to be activated by phorbol esters independent of protein kinase C.I6 Another important bioactivity reported for Sph-l-P is inhibition of conditioned medium-induced motility and phagokinesis of certain tumor cells by unknown mechanism(s).L7.'8
PHINGOSINE (Sph), the fundamental backbone structure of all sphingolipids and glycosphingolipids, and its direct metabolites such as sphingosine-l-phosphate (Sph-1 -P), ceramide (Cer), and N,N-dimethylsphingosine (DMS) have been implicated as lipid second messengers or modulators of membrane signal transduction ~ystems."~ Sph-l-P is the initial product of catabolism of Sph by Sph kinase" and is then cleaved by Sph-l-P lyase to a fatty aldehyde and ethanolamine phosphateg"' or dephosphorylated by a sphingosine phosphatase, as reported recently." The phosphorylated sphingoid base Sph-l-P is not only an intermediary catabolite, but also an important bioactive compound. Sphl-P stimulates DNA synthesis and cell division in Swiss 3T3 fibroblasts, possibly via induction of Ca" mobilization or enhanced phosphatidic acid ~ynthesis.'"'~ Sph-l-P has also been implicated as a novel second messenger in plateletderived growth factor (PDGF) and serum-dependent fibroblast cell growth." In Balb/c 3T3 cells, Sph kinase was reported to be activated by phorbol esters independent of protein kinase C.I6 Another important bioactivity reported for Sph-l-P is inhibition of conditioned medium-induced motility and phagokinesis of certain tumor cells by unknown mechanism(s).L7. '8 Blood platelets are cell fragments containing most of the usual organelles, but lacking a nucleus. Platelets are very sensitive to many diverse agonists and react within seconds of exposure to these stimuli. The process of platelet activation in the circulation must be highly regulated; the cells play a central role in hemostatic reactions, whereas overactive platelets are implicated in the pathogenesis of harmful processes such as atherosclerosis and thrombosis. 19 .20 Interestingly, platelets, which lack the ability to proliferate, possess a very active sphingosine kina~e~.'.~ and practically no lyase activity for degradation of Sph-l-P to a fatty aldehyde and ethanolamine ph~sphate.~.~ These observations suggest important role@) of Sph-l-P in functional responses of highly differentiated cells such as platelets, but few follow-up studies have been performed.
We now show that Sph-1 -P does induce platelet activation.
S
Blood, V01 86, No 1 (July l), 1995 pp 193-202 correlated closely with the concentration required for induction of shape change. On addition of [sHlsphingosine to intact platelets, the label was rapidly converted to Sph-l-P, and subsequently to ceramide and sphingomyelin. Interestingly, the Sph-l-P formed was specifically released into medium on stimulation of platelets with physiologic agonists. The amount of Sph-l-P in platelets, as measured by its conversion into radiolabeled Nacetyl-Sph-l-P, was 1.4 nmoll l@ cells and was about four times higher than the mass of Sph present. When compared by mole percent Sph-l-P1 phospholipid, the value for platelets is over 10 times higher than that for neutrophils. Our results suggest that Sph-l-P, rapidly converted from sphingosine, abundantly stored in platelets, and released on the cell activation, may play a physiologic role in thrombosis, hemostasis, and the natural wound-healing processes. Furthermore, when platelets are incubated with radiolabeled Sph, Sph-l-P is rapidly formed and released into the extracellular environment on stimulation with physiologic agonists. We also show that Sph-l-P is abundantly stored in these anucleate cells. These findings suggest that the phosphorylated sphingolipid may act as a local mediator in control of hemostasis and thrombosis.
MATERIALS AND METHODS

Materials.
Sph-l-P was prepared from sphingosylphosphocholine with bacterial phospholipase D as described previously.21 Nacetyl-Sph (C2-Cer), N-octanoyl ceramide (CS-Cer)?* and DMSU were synthesized as described previously. 
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Platelet preparation.
Washed platelets were prepared as described previously.*' The platelets were finally resuspended in a buffer containing l38 mmolL NaC1, 3.3 mmol/L NaH2P04, 2.9 mmol/L KCI, 1.0 mmoVL MgCI,, 1 mg/mL of glucose, and 20 mmol/L HEPES (pH 7.4). The NaH2P04 was omitted when indicated. The suspensions were adjusted to 3 X IOX/mL and supplemented with I mmol/L CaCI2 unless stated otherwise.
For shape change studies, the platelets, after final centrifugation, were left for at least 60 minutes at 37°C because this resulted in greater response. All experiments using intact platelet suspensions were performed at 3 7°C.
Platelet aggregation und shape change.
These processes were determined in a Platelet Ionized Calcium Aggregometer (ChronoLog, Havertown, PA), with stirring at 1,000 rpm. The instrument was calibrated with a platelet suspension for zero light transmission and the buffer for 100% transmission. When aggregation was measured, human fibrinogen (500 pg/mL) was added to platelet suspensions shortly before the addition of stimuli unless stated otherwise. The increase in light transmission caused by platelet aggregation'5 was continuously recorded.
Shape change was observed by adding 5 mmolL EDTA (instead of Ca2+) before administration of stimuli to prevent aggregation and indicated by a decrease in light For quantitative evaluation of both processes, results were expressed as the maximum change of light transmission within S minutes after stimulation.
Scanning electron microscopy of platelets. Platelet suspensions (0.5 mL) were transferred to 1 mL of a solution of 2% parafonnaldehyde and 2.5% glutaraldehyde in 0.2 moln cacodylate buffer for fixation. Mixtures were dropped onto polylysin-coated 12 mm coverslips and left for 30 minutes. The coverslips were fixed for I S minutes in osmium tetraoxide. The samples were ethanol-dehydrated, critical point-dried, and coated with IS nm goldlpaladium. The intracellular Ca2' concentration ([Ca*']i) meusurement. [Ca*+]i measurement was performed with the use of Ca2+-sensitive fluorophore fura2 as described previously,2' except that the fluorescence measurements were made using a Perkin-Elmer LSSOB (Norwalk, CT).
Metabolism of ["H]Sph in platelets.
Platelet suspensions (0.5 mL) were incubated with 1 pmollL ['HISph (0.2 pCi). At the indicated time points, the reaction was terminated by addition of 1.875 mL of ice-cold chlorofordmethanollconcentrated HCI (100:200: I), and lipids were extracted from the cell suspensions and the phases separated by the method of Bligh and Dyer.2x The upper aqueous phase samples were neutralized with NH40H and then dried completely. The lipids were recovered in 1 mL chlorofordmethanol (2: I ) with sonication. After centrifugation at 1,OOOg for 10 minutes, the added chloroforndmethanol was transferred to another tube, and thus separated from precipitated salt. This desalinization procedure was repeated once. Finally, samples were dried and resuspended in small volumes of chlorofordmethanol (2:l). The lower chloroform phase samples were dried and then resuspended in small volumes of chlorofordmethanol (2:l). Portions of lipids obtained from each phase were applied to silica gel 60 HPTLC plates (Merck, Darmstadt, Germany), and the plates were developed in chloroforndmethanol/ water (65:35:X) for upper phase separation and butanolkacetic acid/ water (3: 1 : I ) for lower phase separation, with appropriate standards. The bands were identified by staining the control lipids with primulin, and visualized under ultraviolet (UV) light, After enhancer (Resolution TLC; E.M. Corp, Chestnut Hill, MA) treatment of thin layer chromatography (TLC) plates, autoradiography was performed with Kodak X-Omat film (Eastman Kodak, Rochester, NY) at -80°C for I to 3 days. The silica gel areas containing the radiolabeled sphingolipids were scraped off and counted by liquid scintillation counting. Under these conditions, Cer was completely recovered in the lower phase; no Cer bands were detected in upper phase samples. Sph and Sph-l-P bands were detected in both upper and lower phases. Recoveries in the lower phase of Sph and Sph-l-P were 8S% and SO%, respectively. Furthermore, levels of Sph-l-P in the two phases always correlated well with each other. Accordingly. only gel autoradiograms obtained from lower phases are shown (see Figs 7 through 9).
When indicated, samples, at the appointed times, were centrifuged for IS seconds at 12,OOOg. Lipids were then extracted from the resultant supernatant and cell pellet and analyzed as described above.
Metaholism of ["CIDMS in platelets.
Platelet suspensions (0.5 mL) were incubated with I O pmol/L ["CIDMS (4 X IOJ cpm). At the indicated times, the reaction was terminated and lipids were extracted from platelet suspensions as described above. Lower phase samples were dried and resuspended in small volumes of chloroform/ methanol (2:l). Portions of lipids were applied to silica gel 60 HPTLC plates, which were then developed in butanol/acetic acid/ water (3: 1 : l ) with appropriate standards.
[I4C]DMS metabolism was evaluated by autoradiography, as described above.
Quantitutivr measurement of the mass (g Sph-I-P in platelets.
The cellular amounts of Sph-l-P were measured by quantitative
by acylation with ['Hlacetic anhydride, which will be described in detail elsewhere (Y. Yatomi et al, manuscript submitted for publication). Platelet suspensions were adjusted to I to 2 X IO'lmL and to the 0.5-mL aliquots was added 3 mL of chloroforndmethanol ( l :2), followed by thorough mixing and sonication for 5 minutes. Phases were separated by further adding 2 mL of chloroform. 2 mL o f I moVL KCI, and 100 pL NH,OH. Three milliliter of chloroform and 200 p L of concentrated HCI were added to the alkaline upper phases, where over 90% of Sph-l-P had been recovered. Under these new acidic conditions, 50% of Sph-l-P shifted to the lower chloroform phases, which were evaporated under NZ. The dried samples were dissolved in 40 pL of 0.008 N NaOH in methanoVl0 mmollL solution of ('Hlacetic anhydride (1: I ) by sonication. Acylation reactions were allowed to proceed at 37°C for I or 2 hours. The remaining anhydride was hydrolyzed by addition of 0.2 mL of 0.2 N NaOH in methanol. After a l-hour incubation at room temperature. the C2-Cer-l -P formed was extracted by addition of 0.78 mL methanol, 0.98 mL chloroform, 0.9 mL I molL NaCI, and 20 pL concentrated HCI. The lower chloroform phase was washed twice by I mL of chloroforndmethanollwater (3/48/47) plus I O pL of concentrated HCI. Samples from the chloroform phase were evaporated under Nz and then resuspended in small volumes of chlorofordmethanol (2:l). Portions of the lipids obtained were applied to silica gel 60 HPTLC plates and the plates were developed in butanol/acetic acid/ water (3: 1 :l), chloroformlmethanoV7 N NH40Wwater in cell extracts were. calculated by extrapolation from Sph-l-P standards, which were run thmugh the same procedures. Production of C2-Cer-l-P under our conditions was identified separately by fast atom bombardment mass spectrometry (FAB-MS) analysis using nonradioactive acetic anhydride (data not shown). Furthermore, the product of N-acylation with ['Hlacetic anhydride of Sph-1 -P, prepared from sphingosylphosphocholine with phospholipase D and one extracted from platelets, coincided with the FAB-MS-identified C2-Cer-l-P in the TLC mobility under three different solvent systems described above (data not shown).
Quantitative measurement of the mass of Sph in platelets. The lower chloroform samples, obtained when the phases were separated in the alkaline conditions for quantification of Sph-l-P mass (see above), were assayed for the mass measurement of Sph present in platelet extracts. This Phospholipid quanti$cation. Platelets were suspended in 0.8 mL of the above indicated buffer without NaH2P0,. Then, lipids were extracted as described previouslyz9 and assayed for phosphorus quantification, which was performed by the method of Chen et al.''
RESULTS
Effects of Sph-l -P on functional responses of humanplatelets. Human platelets underwent significant, although weak and reversible, aggregation reaction when treated with 40 pmoVL Sph-l-P (Fig IA) . This aggregation was completely abolished when extracellular fibrinogen was omitted or 1 mmom EGTA was added instead of 1 mmoVL Ca2+ (data not shown). Aggregation of platelets is a consequence of exposure of the fibrinogen receptor glycoprotein IIb-IIIa3' on the surface of the cells. These receptors bind fibrinogen in the presence of extracellular Ca" and crosslink platelets to form the aggregate.19,25,31 Our results, therefore, indicate that Sph-l-P activates platelets and converts the glycoprotein IIb-IIIa complex to a functional fibrinogen receptor.
We next measured platelet shape change. The decrease of light transmission of a stirred platelet suspension monitored the change from discoid to spheroid ~hape.'~.'~ Administration of Sph-l-P resulted in rapid shape change (Fig 1B) in a concentration-dependent manner (Fig 2) . We also performed scanning electron microscopy to determine platelet shape change. Under these conditions, more than 90% of platelets 195 were discoid and lacked pseudopodia before stimulation ( Fig  3A) . After exposure to Sph-l-P, nearly all platelets changed to spheroids with numerous pseudopodia (Fig 3B) . The turbidometrically detected shape change caused by 40 pmoVL Sph-l-P was comparable to that caused by 5 pg/mL of collagen (Fig 4) , a well-known platelet agonist.I9 The shape change induced by Sph-1 -P, as well as that induced by collagen, was inhibited by cytochalasin B (Fig 4c) , cytochalasin D (data not shown), and prostaglandin El (Fig 4d) . Cytochalasins reportedly inhibit actin polymerization and related shape change in platelet^.^^*^^ Prostaglandin El binds its receptor on the cell surface, which activates adenylate cyclase through mediation by stimulatory guanosine triphosphate (GTP)-binding protein." Elevated CAMP inhibits platelet activation at several phases," including shape change:6 in agreement with our results. It appears likely that the mechanism of shape change reaction induced by Sph-l-P is similar to that induced by well-studied physiologic agonists. Preincubation of platelets with a cyclooxygenase inhibitor, acetylsalicylic only slightly impaired Sph-1 -P-induced shape change, whereas it strongly inhibited collagen-induced shape change (Fig 4b) . This is consistent with the established concept that collagen stimulation is dependent on phospholipase A, activation, which leads to thromboxane Az generat i~n .~~ Sph-l-P appears to elicit shape change, at least in part, via a thromboxane A,-independent pathway.
These positive effects of Sph-l-P on platelet functional responses were specific; Sph, Cer (type TII), C2-Cer, C8-Cer, DMS, and sphingomyelin did not elicit any aggregation or shape change (data not shown).
Sph-l-P did not elicit secretion of 5-HT; the release induced by 40 pmoVL Sph-l-P challenge was 0.4% ? 0.3%, compared with 60.0% and 17.4% 2 1.9% by S pg/mL of collagen (mean 2 SD, n = 3). Failure of Sph-l-P to elicit S-HT release was reproduced under conditions where the aggregation reaction was observed (data not shown). The inability of Sph-l-P to induce S-HT release is consistent with the fact that Sph-l-Pinduced aggregation requires extracellular fibrinogen; agonists with the ability to release granule contents could induce aggregation without exogenously added fibrinogen because the release reaction provides high concentrations of adhesive proteins (including fibrinogen) from platelet granules.':
S.ynergism between Sph-l-P and a weak platelet agonist in aggregarion. The synergistic interaction of platelet agonists provides an efficient amplification mechanism for platelet activation."J~'s This is particularly true when platelets are challenged with epinephrine or adenosine diphosphate (ADP), which is classified as a weak platelet ag~nist.''.'~.~' Under our experimental conditions, ADP alone, at high concentrations, induced strong aggregation; 10 pmol/L ADP induced SO% to SS% light transmission. At lower concentrations such as l pmol/L, ADP produced little aggregation (Fig S, bottom) . As indicated in Fig 2, 20 pmol/L Sph-l-P induced little aggregation. In the presence of subthreshold concentrations of both of these agents together, marked aggregation occurred, with 45% to SS% light transmission (Fig  S, bottom) . Consistent with the notion that epinephrine per se is not an aggregating agent:' it did not induce platelet aggregation by itself at concentrations below 10 pmol/L, (Fig 5, top) . A similar synergistic effect was seen when the stimuli used were Sph-l-P (20 pmol/L) and epinephrine (2 pmol/L) (Fig S, top) . This is in agreement with previous reports on potentiating effects of epinephrine on platelet acti- after Sph-l-P addition and are from a single experiment representative of three.
Sph-I-P-induced intracellular ea2+ mobilization in platelets. It is acknowledged that intracellular
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in other cell Accordingly, we studied the effects of Sph-l-P on Ca2+ levels in human platelets. Sph-l-P induced a prompt increase in [Ca2+]i, the peak value obtained within 20 seconds of addition (Fig 6A) . The increase induced by 40 pmol/L. Sph-l-P was 124 -+-10 nmoVL (mean 2 SD, n = 3) in the presence of extracellular Ca2+, and 68 -C 7 nmoVL (mean ? SD, n = 3) when 1 mmoVL EGTA, instead of Ca2+ was added to chelate extracellular Ca2+. The concentration-dependency for Ca" release induced by Sph-l-P ( Fig  6B) correlated closely with the concentration required for shape change (Fig 2) .
Metabolic conversion of [3wSph in platelets. We studied the metabolic fate of Sph in intact platelets by exogenous addition of ['HISph into the cell suspensions. Uptake of [3H]Sph was 84% at 5 minutes after the label addition when it was determined as the ratio of radioactivity in the platelet pellet, formed by centrifugation, to total added radioactivity. This is consistent with the fact that the label was efficiently removed from the medium when examined by TLC autoradiography (Fig 7, see below) and the previous study reporting quick uptake and metabolism of ['HISph by intact platelet^.^'
The added [3H]Sph was rapidly converted to Sph-l-P (Fig  7) . Within 5 minutes, the level of Sph-l-P nearly reached a plateau, where 46% of the [3H]Sph added was converted to [3H]Sph-l-P. After 20 minutes, the level slowly declined; 39% of [3H]Sph originally added remained [3H]Sph-l-P at 3 hours. This indicates the stability of Sph-l-P in platelets and contrasts with recently described sphinganine l-phosphate metabolism in cultured skin fibroblasts." The difference may be explained, in part, by the fact that platelets have negligible activity of Sph-l-P lyase, which converts phosphorylated long chain bases into ethanolamine phosphate and a fatty a l d e h~d e .~.~
["HISph was also converted by N-acylation into ceramide4' at later time points (Fig 7) ; S%, 11%, and 14% of added ['HISph was converted into ceramide at 1 hour, 2 hours, and 3 hours, respectively. Ceramide can be used in synthesis of complex sphingolipids such as sphingomyelin and glyc~sphingolipids.~~ However, the incorporation of ['HISph into sphingomyelin was very low with a lag period of 2 hours, and no radioactive glycosphingolipids were detected in platelets under our experimental conditions (Fig 7) .
Complete isotopic equilibrium was not attained within 3 hours after the label addition, as shown by the fact that radioactivity of ['HICer was in gradual increase at the latest time point observed (Fig 7) . However, it should be noted that the ['HISph-l-P radioactivity was constantly much higher than that of ['HISph after 20 minutes (Fig 7) . This suggests that the mass of Sph-1 -P in platelets is much higher than that of Sph.
The ['HISph metabolism described above was not affected by stimulation with thrombin (Fig 8) or collagen (data not  shown) . Therefore, Sph kinase may not be under the control of cellular signals produced by these agonists, eg, Ca2+ mobilization or protein kinase C activation."
For comparison, we also studied [I4C]DMS metabolism in human platelets. In striking contrast with [3H]Sph, [I4C]DMS incubated with platelets was unchanged, regardless of incubation time (data not shown). This is consistent with our previous findings using neutrophils4' and mouse melanoma cells," and indicates that the methyl-derivative of Sph is not a substrate for Sph kinase.
Release of Sph-I-P from activatedplatelets. When ['HISph-labeled platelets were separated from medium by centrifugation and lipids were extracted from platelets and medium, all the labeled lipids, including Sph-l-P, were found to remain associated with the platelets (Fig 7) . We examined whether Sph-l-P is released from platelets activated with physiologic agonists. Platelets activated with thrombin or collagen released a substantial part of newly-formed ['H]- 
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Sph-l-P into the medium, whereas Cer and Sph remained associated with the cells (Fig 9A) . In platelets stimulated with S NIH U/mL of thrombin for 5 minutes, 5.4% -C 1.4% (mean ? SD, n = 5) of Sph-l-P formed was released into the medium. Sph-l -P release from thrombin-activated platelets was inhibited by preincubation with staurosporine, a potent protein kinase inhibit~r,'~"~.''" but not when EDTA was added instead of Ca" (Figs 9B and IOC) . Under our conditions, EDTA inhibited aggregation, but not 5-HT release, induced by thrombin ( Fig IO) ; platelets are unable to aggregate because of impaired fibrinogen binding to the cell surface in the absence of bivalent cations.'".'' As reported previously,4J staurosporine inhibited both aggregation and 5-HT release (Fig IO) , possibly because of protein kinase C inhibition. These results indicate that Sph-l-P release is associated with 5-HT release, but not with aggregation.
High cellular content of Sph-l-P in platelets. Finally, Sph-l-P extracted from platelets was quantified by its conversion to ['H]C2-Cer-I-P by N-acylation with ['Hlacetic anhydride (Fig 1 l) . The mass of Sph-l-P in platelets was calculated as 1.42 ? 0.05 nrnoVl0" cells (mean ? SD, n = 3). On the other hand, the mass of Sph in platelets was 378 -C 52 pmol/lO" cells (mean 2 SD, n = 3). Accordingly, the amount of Sph-l-P present in platelets is about four times higher than that of Sph, the substrate of Sph kinase. The finding that the cellular content of Sph-l-P is much higher than that of Sph had been predicted by the ['HISph labeling studies described earlier (see Fig 7 and its related text) . Furthermore, the mol% Sph-l -P/phospholipid value was calculated as 0.21 l ? 0.014 (mean 2 SD, n = 3) for platelets and over 10 times higher than the value for neutrophils, which was 0.0177 ? 0.0028 (mean 2 SD, n = 3).
DISCUSSION
Platelets show different responses that can be studied separately in vitro but are closely linked during hemostasis in vivo: adhesion, shape change, aggregation, and secretion." If platelets are in suspension, the first response to stimulation is shape change, followed by aggregation and secretion. Metabolic energy is required at all stages of platelet activation, and the different responses have different energy requirements increasing in the order: shape change < aggregation < granule s e c r e t i~n . " .~~~~~ Potent agonists such as thrombin or collagen can elicit all these responses." We show here that Sph-1 -P elicits physiologic responses in human platelets ( Figs I through 3) ; it induces shape change and primary aggregation that is reversible and occurs without release reaction. Activation triggered by Sph-l-P may not be so strong because it does not elicit release reaction, which requires much more energy than aggregation. 
-
Another reaction that is induced by Sph-1 -P and of physiologic importance is its synergism with weak agonists in platelet activation. Subthreshold concentrations of $h-l -P and epinephrine or ADP synergistically induced platelet aggregation (Fig 5) . Multiple signal transduction pathways, including protein kinase C activation and Ca2+ mobilization, are present in platelets. They can induce platelet aggregation and synergize with each ~ther.'".'~~'~~~' Strong physiologic stimuli such as thrombin that activate multiple pathways rapidly elicit functional cell response^.'^.".^^ Weak agonists activate only one or two pathways; epinephrine activates only the inhibitory GTP-binding protein, resulting in adenylate cyclase inhibiti~n,'~."".~ whereas ADP may activate the inhibitory GTP-binding protein and Ca2+ pathway^.".".'^ Presumably, Sph-l-P can activate the selective pathway(s) that are unaffected by epinephrine and ADP.
We also found that Sph-l-P induces intracellular Ca2+
thr thr mobilization in platelets (Fig 6) , as reported previously using other cell
The increase correlated well with its effect on shape change reaction (Fig 2) . Furthermore, the functional responses induced by Sph-I-P such as shape change, aggregation, and synergistic effect in aggregation with epinephrine were all mimicked by the Ca*+-ionophore ionomycin under the same conditions (data not shown). Therefore, intracellular Ca2' mobilization seems important in Sph-l -P-induced platelet activation, although we cannot rule out the possibility that other intracellular pathway(s) are activated by this phosphorylated Sph.
We next studied ['HISph metabolism in intact platelets (Figs 7 through 9) . Exogenous Sph can generally be converted via the following metabolic pathways: ( I ) resynthesis to ceramide, which is utilized in synthesis of sphingomyelin and glycosphingolipids;'.j2 (2) conversion to Sph-l N-methylation by methyltransferase was also observed in C2-Cer--
mation of thromboxane A2 and secretion of ADP.'' These substances, liberated from activated platelets, bind to specific receptors and trigger a similar chain of molecular events as the other physiological ~timuli,'~.'~ thereby amplifying platelet responses. Because Sph-l-P activates platelets and is released from activated cells, it may be part of the positive feedback process amplifying and propagating platelet activation induced by the agonists. Although the relative inabundance of Sph-l-P in cells and the resultant notion that Sph kinase is the rate-limiting step in the process of the catabolism of Sph were reported prev i o~s l y ,~~'~~'~ the cellular mass of Sph-l-P in platelets was found to be surprisingly high (see Fig 11 and its related  text) . This is most probably due to the facts that platelets possess a very active Sph kina~e~.~.' and that they contain no lyase activity for degradation of Sph-l-P to a fatty aldehyde and ethanolamine pho~phate.".~ At present, we cannot draw a definite conclusion on the physiologic relevance of Sph-I -P-induced platelet functional responses observed here because high concentrations (micromolar levels) of Sph-1 -P were needed for platelet activation and only about 5% of Sph-l-P was released from platelets by thrombin stimulation. However, as described earlier, the amount of Sph-l-P stored in platelets was much higher than had been expected. Furthermore, when platelets are packed by aggregate or plug formation in, for example, atherosclerotic lesions or blood clots, platelets should become leaky or destroyed and release a large part of stored Sph-l-P into the extracellular environment and the local Sphl-P concentrations are expected to attain high levels. Based on the assumption that half of Sph-I -P stored in IO' platelets (approximately 1.4 nmol) is released into the 100 pL space (the packed volume of 10' platelets is much smaller than this), this would amount to roughly 7 pmol/L Sph-l-P concentration, which was shown to induce marked platelet shape change (Fig 2) and intracellular Ca2+ mobilization (Fig 6) . Furthermore, this concentration of Sph-l-P reportedly induces stimulation of cell growth and intracellular Ca2+ mobilization, almost maximally, in Swiss 3T3 fib rob last^.'^.'^ Collectively, Sph-l-P may play a physiologic role in thrombosis, hemostasis. and the natural wound-healing processes.
platelet Fig 11 . Quantification of Sph-l-P in platelets. Known amounts of Sph-l-P (lanes a t o c, 0,100, and 300 pmol; lanes d t o f, 1, 3, and 10 nrnol) and Sphl-P extracted from 0.5 x lo9 platelets (g) were N acylated with 13Hlacetic anhydride into ['H]C2-Cer-l-P for determination of Sph-l-P level in platelets. The product C2-Cer-l-P, the location of which is indicated on the left, is well separated from unknown residues of Wlacetic anhydride on TLC developed with butanollacetic acidlwater 13:1:11. Based on radioactivities of the bands, the amount of Sph-l-P present in platelets, in this case, was calculated as 1.47 nmoll
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The exact mechanism by which Sph-l-P acts on platelets remains undefined, as is the case with other cell types responding to Sph-l-P. considering that Sph-l-P mobilizes intracellular Ca" mobilization in platelets (Fig 6) and that extracellular, but not intracellular, addition of Sph-l-P elicited intracellular Ca" mobilization in Xenopus laevis oocytes:' it is most likely that Sph-l-P acts on a membrane receptor expressed on platelets. This is also consistent with the fact that Sph fails to activate platelets, although its major product is Sph-l-P. That is, Sph-l-P, produced from Sph by cytosolic Sph kinase7.' and stored inside platelets is incapable of activating platelets.
Recently, there has been increased interest in lysophosphatidic acid (LPA) which, like Sph-l-P, is a lyso-type phospholipid possessing a variety of cellular a~tions.'~-'~ Two actions shared by LPA and Sph-l-P are platelet aggregation (this report) and fibroblast mitogenesis.""' There are several functional and structural similarities between the sphingosine-based Sph-l-P and the glycerol-based LPA. This suggests the possibility of Sph-l-P acting through the LPA receptor, which has recently been shown to be coupled to several GTP-binding protein^.".^^.^^ In favor of this, LPA, as well as Sph-l-P, elicited intracellular Ca2+ mobilization in platelets (data not s h o~n ) .~' However, in Swiss 3T3 fibroblasts, it has been reported that LPA markedly stimulates arachidonic acid release, while Sph-l-P, in contrast, does n~t . '~.~' Furthermore, we recently found that tumor cell motility is strongly regulated by Sph-1-P,'7,'8 but not LPA (Y. Sadahira et al. manuscript submitted for publication). These may indicate that the above-mentioned possibility is remote. It is difficult to identify and characterize receptors for lipid mediators. It was not until recent reports by van der Bend et and Thomson et alS6 that specific LPA binding sites were found in cell membranes. As for Sph-l-P receptor, little has been reported. In fact, we could not detect specific [32P]Sph-1-P binding to cell membranes, perhaps because of the high lipophilicity of the ligand, resulting in extensive intercalation into the lipid bilayer. Presumably, different strategies are needed to clarify the possible Sph-1 -P receptor.
